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DOI 10.1016/j.ccr.2011.08.010SUMMARYThe development of resistance to chemotherapy is a major obstacle for lasting effective treatment of cancer.
Here, we demonstrate that endogenousmesenchymal stem cells (MSCs) become activated during treatment
with platinum analogs and secrete factors that protect tumor cells against a range of chemotherapeutics.
Through a metabolomics approach, we identified two distinct platinum-induced polyunsaturated fatty
acids (PIFAs), 12-oxo-5,8,10-heptadecatrienoic acid (KHT) and hexadeca-4,7,10,13-tetraenoic acid
(16:4(n-3)), that in minute quantities induce resistance to a broad spectrum of chemotherapeutic agents.
Interestingly, blocking central enzymes involved in the production of these PIFAs (cyclooxygenase-1
and thromboxane synthase) prevents MSC-induced resistance. Our findings show that MSCs are potent
mediators of resistance to chemotherapy and reveal targets to enhance chemotherapy efficacy in patients.INTRODUCTION
Chemotherapy remains the primary treatment for most dissem-
inated cancers. However, the response to chemotherapy is often
transient, and development of resistance is one of the most
significant obstacles to effective cancer therapy. Although
various tumor cell-intrinsic mechanisms of drug resistance
have been identified, it is becoming increasingly clear that theSignificance
Chemotherapy remains the primary treatment for most dissemi
transient, and the development of resistance is one of the mo
show that mesenchymal stem cells (MSCs) activated by platinu
in minute quantities, confer resistance to multiple types of chem
cancer treatment and reveals a potent effect of two relatively u
approach to enhance the clinical benefit of chemotherapy by b
bition of cyclooxygenase-1 or thromboxane synthase.
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drug resistance (reviewed in Meads et al., 2009). Whereas
acquired tumor cell-intrinsic resistance develops over time, envi-
ronment-mediated drug resistance is rapidly induced by
signaling events from the tumor microenvironment and is likely
reversible because removal of the microenvironment restores
the drug sensitivity (Meads et al., 2009). The important role
of the microenvironment in therapy response is furthernated cancers. However, response to chemotherapy is often
st significant obstacles to effective cancer therapy. We now
m-based chemotherapy secrete two unique fatty acids that,
otherapy. This highlights an undesired role for stem cells in
nknown fatty acids. Finally, our results reveal a therapeutic
locking the release of these fatty acids from MSCs via inhi-
c.
Cancer Cell
Fatty Acids Induce Chemotherapy Resistancedemonstrated by the fact that specific properties of stromal cells
in the tumor microenvironment are often an indicator of poor
prognosis. For instance in breast cancer patients, the stromal
gene expression within the tumor predicts resistance to preoper-
ative chemotherapy (Farmer et al., 2009). The surrounding
stroma is believed to modulate the response to chemotherapy
by either direct cell-cell interactions with tumor cells, or by the
local release of soluble factors such as interleukin-6, promoting
survival and tumor growth (Weaver et al., 2002; Shekhar et al.,
2007; Hazlehurst et al., 2003; Sethi et al., 1999; Mu¨erko¨ster
et al., 2004).
Tumors actively modulate their microenvironment by recruit-
ing inflammatory cells and bone marrow-derived cells (BMDCs)
(Kaplan et al., 2005; Jain and Duda, 2003; Lyden et al., 2001).
It was recently shown that BMDCs can act in an immediate
‘‘seek and repair’’ manner in response to therapy, presumably
in order to support tissue regeneration (Shaked et al., 2008). A
subgroup of these cells, mesenchymal stem cells (MSCs), has
gained much interest as mediators of cancer progression.
MSCs are multipotent cells capable of differentiating into
numerous cell types, including adipocytes, osteoblasts, chon-
drocytes, fibroblasts, and perivascular and vascular structures
(Pittenger et al., 1999; Beckermann et al., 2008; Schmidt et al.,
2006; Ringe et al., 2007). Although MSCs are found predomi-
nantly in the bone marrow (BM), resident MSCs have been
described in various organs, and a small population is retained
in circulation (Young et al., 2001). The relevance of MSCs
becomes apparent in cases of tissue repair, wound healing,
and inflammation. In these conditions paracrine signaling leads
to mobilization of MSCs from BM and subsequent recruitment
to the damaged site (To¨gel et al., 2005; Morigi et al., 2008;
Chen et al., 2008). Importantly, MSCs are recruited in large
numbers to the stroma of developing tumors. Growing tumors
constantly produce paracrine and endocrine signals mobilizing
MSCs from the BM (Kidd et al., 2009; Loebinger et al., 2009;
Schmidt et al., 2006; Ringe et al., 2007). In the tumor, MSCs
are found to stimulate tumor growth, enhance angiogenesis,
and promote metastasis formation through the release of a large
spectrum of growth factors and cytokines (Beckermann et al.,
2008; Karnoub et al., 2007; Bergfeld and DeClerck, 2010; Rho-
des et al., 2010). In this study we addressed if MSCs are also
involved in the development of resistance to chemotherapy.
We investigated whether MSCs, recruited to the circulation by
solid tumors, may play a role in the development of resistance
to multiple types of chemotherapy.
RESULTS
MSCs Induce Resistance to Chemotherapy
To test the hypothesis that MSCs confer resistance to chemo-
therapy, we established different murine tumor models in which
we resembled the mobilization and recruitment of MSCs from
the BM to tumor. MSCs were harvested from the BM of syngenic
mice and injected intravenously (i.v.) in mice bearing a subcuta-
neous (s.c.) tumor. MSCs used were either freshly isolated from
the BM or cultured for five to seven passages to obtain a pure
MSC population before injection (Li et al., 2009; Pevsner-Fischer
et al., 2007). The cultured MSCs were analyzed by FACS anal-
ysis, and the number of cfu-F was determined. MultilineageCandifferentiation potential confirmed the true MSC phenotype
(see Figures S1A and S1B available online). The recruitment of
MSCs to the tumor after i.v. injections has previously been
demonstrated in a variety of animal models (Wang and Dubois,
2010). Consistently, 4 days after i.v. administration of 100,000
MSCs derived from GFP-positive mice, we found GFP-positive
cells specifically in the s.c. tumors (0.05%–0.1% of all cells).
There was no detectable accumulation of MSCs in other organs
such as lungs, kidney, spleen, and liver (Figure S1C). In line with
published data (Karnoub et al., 2007), administration of MSCs
did not alter the growth kinetics of the tumor (Figure S1D).
However, when the mice were treated with a commonly used
chemotherapeutic agent, cisplatin (6 mg/kg), we found that
MSCs administered i.v. just prior to chemotherapy negated the
antitumor effect of cisplatin in a dose-dependent manner
(Figure 1A). Intravenous administration of as few as 50,000
MSCs abolished the antitumor effects of cisplatin and resulted
in a tumor volume similar to the untreated controls (Figure 1A).
These findings were reproduced in two independent, s.c. mouse
tumor models (C26 colon carcinoma cells in BALB/c, and
Lewis lung carcinoma [LLC] cells in C57/Bl6) (Figure 1B), and
were obtained by using both freshly isolated MSCs and cultured
pure MSCs. The size of the tumor did not affect the ability to
induce resistance; in larger tumors a similar effect was seen
(Figure 1C).
MSCs Induce Resistance in a Systemic Manner
Given our observation that MSCs induce resistance to cisplatin
and the notion that only a small number of MSCs engrafted in
the tumors, we hypothesized that the induction of chemoresist-
ance is due to a paracrine or systemic effect instead of an effect
requiring direct cell-cell interaction. To investigate this, we s.c. in-
jected MSCs at a site distant from the tumor. Subcutaneous
MSCs were even more potent in inducing resistance to cisplatin
compared to the i.v. administered MSCs. As few as 1000 MSCs
injected s.c. in the other flank of the mouse than the tumor could
induce partial resistance to cisplatin chemotherapy (Figure 1D).
To provide further support of a systemic effect, we established
in vitro cultures of mouse MSCs and treated mice with daily s.c.
injections of conditioned medium (CM) harvested from cultured
MSCs.Whenwepreincubated culturedMSCswith 1mMcisplatin
for as short as 30min and incubated for only 1 hr with serum-free
medium (SFM) and subsequently administered this CM+ to
tumor-bearing mice at the start of systemic treatment with
cisplatin, we observed complete resistance to cisplatin for both
the C26 tumors and LLC tumors, whereas CM from untreated
MSCs (CM) had no effect on the in vivo response to cisplatin
(Figures 1E and 1F). Together, these data show that MSCs are
rapidly activated by cisplatin to release systemic factors that
subsequently induce resistance to chemotherapy.
Platinum-Activated MSCs Confer Resistance to Various
Chemotherapeutics
To determine whether other chemotherapeutic agents could
elicit the same MSC-induced resistance response, we tested
different types of chemotherapy in our tumor models. Interest-
ingly, in vivo resistance was only induced by MSCs in combina-
tion with MTD administration of the platinum analogs cisplatin,
oxaliplatin (10 mg/kg), or carboplatin (100 mg/kg), but not withcer Cell 20, 370–383, September 13, 2011 ª2011 Elsevier Inc. 371
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Figure 1. MSCs Induce Resistance to Cisplatin in a Paracrine Fashion
(A) Tumor volume of C26 cells inoculated s.c. in BALB/c mice 4 days after treatment with either vehicle control, cisplatin (6 mg/kg) or cisplatin plus coadmin-
istration of 100,000, 50,000, or 10,000 MSCs i.v. Treatment was initiated when tumors reached a volume of 50–100 mm3.
(B) Tumor growth of LLC cells inoculated s.c. in C57Bl/6 mice, either untreated or treated with cisplatin alone or with cisplatin plus 100,000 MSCs i.v.
(C) Tumor volume of C26 cells 4 days after treatment with either vehicle control, cisplatin (6 mg/kg) or cisplatin plus coadministration of 50,000 MSCs i.v.
Treatment was initiated when tumors reached a volume of 400–500 mm3.
(D) Tumor volume of C26 cells 4 days after treatment with cisplatin with or without coadministration of MSCs s.c. in the other flank of the mouse (10,000, 1,000, or
100 MSCs).
(E) Tumor growth of C26 cells inoculated s.c. either untreated, treated with cisplatin alone or with cisplatin plus s.c. injections of 100 ml of the CM+ or CM.
(F) Tumor growth of LLC cells either untreated, treated with cisplatin alone or with cisplatin plus s.c. injections of the CM+.
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Cancer Cell
Fatty Acids Induce Chemotherapy Resistance5-FU (100 mg/kg) or irinotecan (100 mg/kg) (Figure 2A). We next
tested CM obtained from MSCs incubated with 1 mM of different
types of chemotherapy. We found that only CM of MSCs prein-
cubated with platinum analogs for 30 min followed by a serum
free medium (SFM) incubation of 2 hr was able to induce resis-
tance. The CM of MSCs preincubated with 5-FU, irinotecan,
paclitaxel, or doxorubicin could not induce resistance in vivo
(Figure 2B). Alternatively, we investigated whether platinum-acti-
vated MSCs could provide protection against other chemother-
apeutic agents. Therefore, we treated tumor-bearing mice with
either 5-FU or irinotecan in combination with daily s.c. injections
of CM+ from cisplatin-preincubated cultured MSCs. Interest-
ingly, we found that CM+ effectively induced resistance to
both 5-FU and irinotecan (Figure 2C). To show that also the
endogenous MSCs, present in the circulation of tumor-bearing
mice, can be activated by platinum to secrete the resistance-
inducing factors, we treated tumor-bearing mice with cisplatin,
and after 30 min we harvested the MSCs from the circulation
of these mice. These MSCs were subsequently injected s.c.
into a recipient tumor-bearing mouse concomitantly with irinote-
can treatment, which does not activate MSCs to produce the
systemic factors in vivo. Strikingly, we found that indeed these
MSCs induced resistance to irinotecan (Figure 2D), showing
that endogenous, circulating MSCs are activated by platinum-
based chemotherapy to secrete the resistance-inducing factors.
Therefore, we concluded that MSCs need to be activated by
a platinum-based chemotherapeutic agent in order to confer
resistance and that the secreted factor(s) induces resistance
against various types of chemotherapy. The fact that the
secreted factor(s) induces resistance to very different types of
chemotherapy suggests a general mechanism of protection of
the tumor at the level of apoptosis.
To investigate whether the release of chemoprotective factors
in response to platinum-based chemotherapy is a MSC-specific
phenomenon, we tested different cell types for their ability to
induce resistance in response to cisplatin. Hematopoietic stem
cells (HSCs) and mature hematopoietic cells could not mimic
the effects obtained with MSCs (data not shown). Next, we
tested whether more differentiated mesenchymal cells could
produce the protective factor(s) in response to cisplatin. We
tested CM+ from mouse embryonic fibroblasts (MEFs), fibro-
blasts (3T3), preadipocytes (3T3-L1), differentiated adipocytes,
preosteoblasts (MC3T3), and differentiated osteoblasts, and
found that in addition to MSCs, only CM+ from MEFs could
induce resistance in our mouse models. CM+ harvested from
more differentiated cell lines did not induce resistance in vivo
(Figure 2E). These findings indicate that only mesenchymal cells
with amultilineage differentiation potential such asMSCs orMEF
cells retain the capacity to secrete chemoprotective factors in
response to platinum-based chemotherapy.
Systemic Induction of Resistance via Indirect
and Reversible Prevention of Apoptosis
We showed that a single dose of the CM+ was sufficient to
induce resistance. However, the CM+ had to be administeredThe graphs depict representative results from four individual experiments. Studen
expressed as mean ± SEM (n = 6 mice per group).
See also Figure S1.
Canwithin 3 hr after cisplatin treatment to exert the protective effect
(Figure 3A), indicating that the protective factors in the CM+
intervene with the early effects of chemotherapy. Interestingly,
the tumor-protective effect exerted by CM+ was reversible
because omitting the coadministration of the CM+ during
a subsequent cycle of cisplatin restored the sensitivity to chemo-
therapy (Figure 3B). Therefore, we concluded that the secreted
factor(s) did not induce persistent changes in the tumor but
induced an acute and reversible protection of the tumor cells.
Correspondingly, we did not find any changes in the amount of
tumor stroma, microvascular density, or macrophages infiltra-
tion, evaluated by smooth muscle actin, desmin, vWf, F4/80
stainings, and rhodamine dextran injections (Figures S2A and
S2B). However, both injection of MSCs and CM+ significantly
reduced the number of apoptotic caspase-3-positive tumor cells
by 50% to less than 2.5% (p < 0.01, Student’s t test) in compar-
ison to 5% in the tumors treated with cisplatin alone (Figure 3C).
No difference in proliferation was observed as measured by
Ki-67 (data not shown) or BrdU staining. (Figure 3D). The reduc-
tion in apoptosis is not due to a reduced exposure to chemo-
therapy. Similar chemotherapeutic exposure of the tumors was
confirmed by pharmacokinetics (PK) of both cisplatin and
irinotecan in plasma and tumor tissue. No differences were
observed in the PK of cisplatin or in irinotecan (CPT-11) and its
active metabolite SN-38 in the presence or absence of CM+.
(Figure S2C). Therefore, altered PK of cisplatin or irinotecan
could not account for the observed resistance.
To evaluate whether the systemic factors induce resistance to
the tumor cells directly, we established an in vitro model in which
we either performed cocultures of MSCs and tumor cells or
treated the cultured tumor cells with chemotherapy in combina-
tion with the CM+ from the MSCs. We found that in vitro neither
coculture with MSC nor incubation with CM+ could directly
protect the tumor cells against chemotherapy, and no induction
of resistance was observed (Figure 3E). This suggests the
requirement of secondary secreted host factors. Indeed, we
found that plasma, obtained from nontumor-bearing mice 1 hr
after administration of the CM+, did induce resistance to
cisplatin and irinotecan in our in vitro system (Figure 3F). We
excluded the requirement of a potential cofactor from the plasma
by adding the CM+ to plasma from untreated mice. This could
not induce resistance (data not shown). In conclusion the induc-
tion of resistance to chemotherapy is not mediated via a direct
effect of the systemic factors on the tumor cells but likely via
the release of an intermediate factor(s) by the host tissue in the
plasma that then directly prevents the induction of apoptosis in
the tumor cells by chemotherapy.
MSC-Induced Resistance Is Mediated by the Release
of Polyunsaturated Fatty Acids
In order to identify the resistance-inducing systemic factor(s)
secreted by platinum-activated mouse MSCs, we followed
a systematic metabolomics approach of stepwise CM fraction-
ations (Figure 4A) and tested each fraction for its ability to induce
chemoresistance in vivo. First, CM+ was separated into twot’s t test, all compared to chemotherapy alone: **p < 0.01, ***p < 0.001. Data are
cer Cell 20, 370–383, September 13, 2011 ª2011 Elsevier Inc. 373
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Figure 2. In Response to Platinum-Based Chemotherapy, MSCs Induce Resistance to Multiple Types of Chemotherapy
(A) Tumor volume of C26 cells 4 days after treatment with either oxaliplatin (10 mg/kg), carboplatin, irinotecan, and 5-FU (all 100 mg/kg) alone, or in combination
with 100,000 MSCs i.v.
(B) Tumor volume of C26 cells 4 days after treatment with cisplatin alone or in combination with the CM from MSCs preincubated with different types of
chemotherapy.
(C) Tumor volume of C26 cells 4 days after treatment with either 5-FU or irinotecan (both 100 mg/kg) alone or in combination with s.c. injections of CM+ from
cultured MSCs preincubated with cisplatin (n = 3 mice per group).
(D) A total of 1000 circulating MSCs, harvested from the blood of tumor-bearing mice 30 min after treatment with cisplatin, was s.c. injected into tumor-bearing
mice concomitantly with irinotecan treatment. Tumor growth of C26 cells either treated with vehicle control, irinotecan alone or irinotecan plus MSCs is
plotted.
(E) Tumor volume 4 days after treatment with cisplatin in combination with s.c. injections of CM+ from the different cell types preincubated with cisplatin.
Data are expressed as mean ± SEM (n = 6 mice per group). The graphs depict representative results from three individual experiments. Student’s t test,
all compared to chemotherapy alone: nonsignificant (NS) p > 0.05, *p < 0.05, **p < 0.01.
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Figure 4. Systematic Fractionation of CM Reveals that the Secretion of Distinct Fatty Acids Induces Resistance
(A) CM from mouse MSCs was stepwise fractionated by size, liquid-liquid, and SPE resulting in a separation by lipid class. The FFAs were further fractionated
based on degree of saturation. The ability of induction of resistance of each fraction was tested.
(B and G) Percent (%) change in tumor volume 4 days after start of therapy of C26 tumors, either untreated, treated with cisplatin alone or with one concomitant
dose of the fractions of the CM+ or individual factors s.c. (n = 4 mice per group).
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Fatty Acids Induce Chemotherapy Resistancefractions based on size, using a 5 kDa cutoff to roughly distin-
guish between proteins and metabolites. Only the fraction con-
taining the components smaller than 5 kDa induced resistance
(Figure 4B). Liquid-liquid extraction was then performed that
pointed to the presence of the active components in the apolar
fraction (Figures 4A and 4B), suggesting the involvement of
lipid-like factors. We next performed aminopropyl-Si solid phase
extraction (SPE) to enrich for different lipid classes and found
that only fraction B from CM+ retained the potential to induce
resistance (Figures 4B and 4C). To characterize the differentially
regulated CM metabolites in more detail, we subjected fraction
B, enriched for free fatty acids (FFAs), to UPLC-Orbitrap mass
spectrometry (MS), which enables accurate mass measurement
and, thus, determination of the elemental composition of identi-
fied components. A highly complex mixture was observed (Fig-
ure S3A) including 69 factors with a FFA elemental composition
(Table S1), 17 of which were differentially present in the CM+
compared to CM (Figure 4D). To further reduce complexity,
fraction B was separated by Ag-ion SPE based on the saturation
level of the fatty acids. This resulted in two fractions that inde-
pendently induced resistance in the mouse model (Figure 4G),
suggesting that at least two factors are involved. MS experi-
ments unambiguously identified the elemental composition of
three masses: one differentially regulated FFA in fractions 3
and 5 with identical elemental composition, and two additional
FFAs in fraction 5 (Figures 4D and S3B–S3F, and Table S2).
The chromatographic properties in combination with the
elemental composition and spectral fragmentation patterns by
Orbitrap MS (data not shown) allowed us to propose that in
fractions 3 and 5 the elemental composition C17H26O3 belonged
to 12-oxo-5,8,10-heptadecatrienoic acid (KHT), whereas in frac-
tion 5, C16H24O2 belonged to hexadeca-4,7,10,13-tetraenoic
acid (16:4(n-3)) (Figures 4E and 4F). The identity of C15H22O2
could not be unambiguously determined. To confirm our find-
ings, we injected tumor-bearing mice with as little as 2 pmol of
the KHT precursor HHT, which is readily converted to KHT (Agins
et al., 1987), and 2.5 pmol of the purified 16:4(n-3) (Ishihara et al.,
2000), and found that each of the PIFAs individually induced
complete resistance to cisplatin (Figure 4H), whereas a range
of other polyunsaturated fatty acids was inactive (Figure 4H
and Table S3). Notably, the pure PIFAs did not enhance tumor
growth without the administration of cisplatin (Figure 4H).
Wewereable todevelopa sensitiveMSassayonly for 16:4(n-3)
because we had access to the purified 16:4(n-3), whereas we
unfortunately donot havepurifiedKHT.Using this assay,weeval-
uated the kinetics of the release of 16:4(n-3) by the MSCs in
response to chemotherapy. Incubation of the MSCs with 1 mM
of the platinum compounds cisplatin, oxaliplatin, and carboplatin
resulted in a 2.5-, 2.8-, and 2.8-fold increase of 16:4(n-3) relative(C) Tumor growth of C26 cells either untreated, treated with cisplatin alone or
or CM (s.c.).
(D) Differentially regulated fatty acids in the CM+/CM fractions B, 3, and 5. The e
map. FC, fold change.
(E and F) Chemical structure of the identified PIFAs.
(H) Tumor volume 4 days after treatment with the PIFAs alone, cisplatin alone,
16:4(n-3), or similar fatty acids as controls (n = 6 mice per group).
The graphs depict representative results from two individual experiments. Data a
alone: *p < 0.05, **p < 0.01, ***p < 0.001.
See also Figure S3 and Tables S1–S3.
Canto CM. In linewith the in vivo experiments, incubating theMSCs
with the same concentrations of other chemotherapeutics did
not, or to a lesser extent, lead to an increase in 16:4(n-3) i.e., 5-
FU increased 0.77-fold, irinotecan 1.74-fold, doxorubicin 0.73-
fold, and paclitaxel induced a 1.55-fold increase compared to
the CM. When we incubated MSCs with increasing concentra-
tions of cisplatin, we found a dose-dependent increase of 16:4(n-
3) in the CM (Figure S3G). This shows that the platinum-based
chemotherapeutics are most powerful in inducing the release of
16:4(n-3), and that that effect is dose dependent.
MSC-Induced Resistance Is Prevented by Intervening
with the Cyclooxygenase (COX)-1/Thromboxane
Synthase (TXAS) Pathway
One of the identified PIFAs, KHT is known to be a by-product of
thromboxane A2 synthesis. In response to various stimuli, often
via an increase in intracellular calcium, phospholipases (PLA2
and PLC) become phosphorylated and, subsequently, release
the large omega-3 and -6 fatty acids eicosapentaenoic acid
(EPA) and arachidonic acid (AA) from the cell membrane. Intra-
cellularly, these FFAs are further processed by the COX pathway
leading to the production of various prostaglandins, leukotri-
enes, and via TXAS to thromboxane A2 (Agins et al., 1987; Nar-
aba et al., 1998). All are rapidly acting and powerful lipids with
broad systemic functions. To test whether intervening with this
process could prevent resistance by the platinum-activated
MSCs, we preincubated the cultured MSCs with various inhibi-
tors targeting all the steps in the pathway, before the incubation
of these MSCs with cisplatin. We used the phospholipase A2
inhibitors MAFP, DEDA, and the selective cPLA2 (calcium-
dependent PLA2) inhibitor pyrrophenone, the phospholipase C
inhibitors U73122 and D609, the intracellular calcium-chelating
agent BAPTA AM, the calcium pump inhibitors verapamil and ni-
cardipine, the COX inhibitor indomethacin, the selective COX-2
inhibitor celecoxib, the selective COX-1 inhibitor SC560, and
the TXAS inhibitors ozagrel and furegrelate. Strikingly, we found
that preincubation with inhibitors of PLA2, COX-1, and TXAS, or
addition of an intracellular calcium chelator, blocked the induc-
tion of resistance by platinum-activated MSCs, whereas inhibi-
tion of PLC, the calcium pumps, or COX-2 had no effect (Fig-
ure 5A). Notably, in the CM of MSCs pretreated with either
indomethacin or ozagrel, the PIFAs were significantly downregu-
lated to levels lower than CM (data not shown). When we
added the PIFAs back to this CM and tested this CM in our
mouse models, this fully restored the ability to induce resistance
(Figure S4A). This suggests that the release of the two PIFAs by
the MSCs in response to cisplatin is mediated by an intracellular
calcium-mediated activation of PLA2, leading to the release of
AA and EPA from the cell membrane that are the substrates forcisplatin plus one concomitant dose of the fatty acid fraction B from CM+
lemental composition as determined by high-accuracy FTMS is shown in a heat
or cisplatin plus one concomitant dose of either the identified PIFAs, KHT or
re expressed as mean ± SEM. Student’s t test, all compared to chemotherapy
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Figure 5. MSC-Induced Resistance Is Prevented by COX-1 Inhibition
(A) Tumor volume of C26 cells 4 days after start of treatment. Mice were either untreated, treated with cisplatin alone or with cisplatin plus s.c. injections of the
CM+ from MSCs pretreated with the phospholipase A2 inhibitors MAFP, DEDA, and the selective cPLA2 inhibitor pyrrophenone, the phospholipase C inhibitors
U73122 and D609, the intracellular calcium-chelating agent BAPTA AM, the calcium pump inhibitors verapamil and nicardipine, the COX inhibitor indomethacin,
the selective COX-2 inhibitor celecoxib, the selective COX-1 inhibitor SC560, and the TXAS inhibitors ozagrel and furegrelate (n = 4 mice per group).
(B) Tumor growth of C26 cells either untreated, treated with cisplatin alone or with cisplatin plus MSC with or without pretreatment with indomethacin (2 mg/kg)
or ozagrel (20 mg/kg) s.c. 1 day and 1 hr before cisplatin (n = 5 mice per group).
Cancer Cell
Fatty Acids Induce Chemotherapy Resistance
378 Cancer Cell 20, 370–383, September 13, 2011 ª2011 Elsevier Inc.
Cancer Cell
Fatty Acids Induce Chemotherapy Resistancefurther conversion by COX and TXAS. In line with these findings,
microarray data, comparing untreated MSCs with cisplatin-
treated MSCs, showed no relevant differences in gene expres-
sion (data not shown). Furthermore, the prior observation that PI-
FAs are already released from MSCs almost immediately after
exposure to cisplatin, within 1.5 hr, also suggests that transcrip-
tional regulation is less likely. In addition, as shown by western
blots, the level of COX remained unchanged in the MSCs after
treatment with cisplatin (data not shown). Together, this
suggests that the increased production of the PIFAs is due to
an increase in the availability of the substrates. Thus far,
16:4(n-3) has only been described to be formed via peroxisomal
oxidation from EPA (Williard et al., 1998). Given our results, it is
likely that similar to KHT, 16:4(n-3) functions downstream of
the COX-TXAS pathway.
We confirmed these findings in vivo and found that, indeed, in
our mice models in which we administrated the MSCs i.v., addi-
tion of only two doses of indomethacin (2 mg/kg) or ozagrel
(20 mg/kg) just before the chemotherapy completely prevented
the MSC-induced resistance (Figure 5B). The role of MSC-medi-
ated fatty acid production in chemoresistance was further
supported by the observation that in both C26 tumors and
LLC tumors, without the administration of additional MSCs,
indomethacin and ozagrel significantly enhanced the antitumor
efficacy of cisplatin and oxaliplatin alone in vivo (Figures 5C–5E;
Figures S4B and S4C). Interestingly, neither indomethacin nor
ozagrel alone had any antitumor effect when administered on
this dosing schedule. Notably, indomethacin did not enhance
the efficacy of cisplatin in vitro (Figure 5F), which could suggest
that addition of indomethacin or ozagrel enhances the antitumor
efficacy of cisplatin by preventing the platinum-induced activa-
tion and subsequent PIFA release by the endogenous MSCs
in vivo. This is supported by the fact that indomethacin did
not enhance the antitumor efficacy of irinotecan in vivo
(Figure S4D).
In conclusion these experiments indicate that specifically
TXAS and COX-1, but not COX-2, inhibition prevented MSC-
induced resistance and enhanced chemotherapy efficacy.
Therefore, these results support the notion that inhibition of
COX-1/TXAS pathways could provide a drugable target to
prevent PIFA-induced chemoresistance.
Evidence for the Clinical Relevance of MSC-Induced
Resistance to Chemotherapy
To validate our findings in cancer patients, we first measured
the levels of MSCs in whole blood of a group of 50 cancer
patients with different types of tumors. We found a significant
increase in MSC levels in the peripheral blood of cancer patients
with metastatic disease compared to cancer patients after
radical resection of the tumor with no evidence of residual(C–E) Tumor growth of C26 cells untreated, treatedwith cisplatin (C and D) or oxali
indomethacin (C), cisplatin and ozagrel (D), or oxaliplatin and indomethacin (E).
cisplatin or vehicle control at days 8 and 14 after tumor cell inoculation (n = 8 m
experiments.
(F) In vitro cytotoxicity of cisplatin (3 mM), indomethacin, or cisplatin plus indometh
cells were counted 24 and 48 hr after start of therapy.
Data are expressed as mean ± SEM. Student’s t test, all compared to chemothe
See also Figure S4.
Candisease (Figure S5A). These findings indicate that MSCs are
present in the circulation and, therefore, will be exposed to
chemotherapy. Furthermore, the number of circulating MSCs
is comparable to the number of MSCs sufficient to confer
chemoresistance in mouse models. To demonstrate the clinical
relevance of our findings, we isolatedMSCs from the BMof three
healthy human volunteers. MSCs from each donor were cultured
and characterized by FACS analysis, the number of cfu-F
was determined, and MSC phenotype was confirmed by multili-
neage differentiation potential into chondrocytes, adipocytes,
and osteoblasts (Figures S5B and S5C). The results of these
extensive characterizations were previously published (Prins
et al., 2009; Siddappa et al., 2008). MSCs from each subject
were injected i.v. in nude mice bearing s.c. growing human
MDA-MB-231 breast cancer cells. Each human MSC isolate
induced a similar cisplatin resistance as previously observed
for mouse MSCs. Furthermore, treatment of these mice with
weekly cisplatin for 5 weeks showed that the protective effect
of the MSCs, administered only before the first dosage of
cisplatin, persisted during the following cycles of chemotherapy
(Figures 6A and 6B). From these experiments we concluded that
both mouse and human MSCs can induce resistance in
response to cisplatin treatment when added to the circulation
of tumor-bearing mice. Furthermore, mice treated with daily
s.c. injections of CM harvested from cisplatin-preincubated
cultures of human MSCs (CM+) became completely resistant
to cisplatin. CM from untreated human MSCs (CM) had no
effect on the in vivo response to cisplatin (Figure 6C). Through
MS we confirmed the presence of 16:4(n-3) and KHT in the
CM+ of activated human MSCs similar to PIFAs secreted by
mouse MSCs (Figure S5D). Finally, we measured the levels of
16:4(n-3) in plasma samples from ten esophageal cancer
patients treated with cisplatin-based chemotherapy and ten
breast cancer patients treated with nonplatinum-based chemo-
therapy. In an exploratory analysis we found a significant
increase in 16:4(n-3) hours after treatment with cisplatin-based
chemotherapy compared to the patients treated with nonplati-
num-based chemotherapy (p = 0.04) (Figure 6D). Overall, based
on the preclinical data and exploratory clinical data, these results
indicate that our identifiedmechanism of resistance byMSCs via
the release of PIFAs can be translated to the clinic.
Fatty acids are also present in various food products and
supplements. We found that our identified PIFA 16:4(n-3) is
abundantly present in commercially available fish oil products
(0.4–0.6mM 16:4(n-3)) and algae extracts (27mM 16:4(n-3)). Fish
oil products are frequently used by cancer patients because of
their perceived positive health effects, such as preventing
cachexia and cardiovascular events, anti-inflammatory proper-
ties, prevention of tumor growth, and reduction of chemo-
therapy-induced side effects (Berquin et al., 2008; Jiang et al.,platin (E) alone, indomethacin (C and E) or ozagrel (D) alone, or with cisplatin and
Both indomethacin and ozagrel were administered s.c. 1 day and 1 hr before
ice per group). The graphs depict representative results from three individual
acin. Indomethacin was administered at doses ranging from 1 to 100 mM. Viable
rapy alone: *p < 0.05, **p < 0.01.
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Figure 6. Human MSCs Secrete the Same PIFAs that Induce Resistance in a Breast Cancer Xenograft Model
(A and B) Tumor growth of MDA-MB-231 cells treated with either vehicle control, cisplatin or with cisplatin plus 100,000 i.v.-injected human MSCs concurrently
with only the first administration of the cisplatin (6 mg/kg). Cisplatin therapy was repeated weekly (arrows) (n = 5 mice per group).
(C) Tumor growth of MDA-MB-231 cells either untreated, treated with cisplatin alone weekly or with cisplatin weekly plus 100 ml CM+ (s.c.) from human MSCs
derived from three healthy individuals (n = 5 mice per group). The graphs depict representative results from two individual experiments.
(D) 16:4(n-3) levels were measured using MS in plasma samples from esophageal cancer patients (n = 10) treated with cisplatin-based therapy compared to
breast cancer patients (n = 10) treatedwith nonplatinum-based therapy. Percent (%) change is shown between baseline and 2–4 hr after chemotherapy (p = 0.04).
Data are expressed as mean ± SEM. Student’s t test, compared to chemotherapy alone unless otherwise indicated: *p < 0.05, **p < 0.01.
See also Figure S5.
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Fatty Acids Induce Chemotherapy Resistance2010; Shaikh et al., 2010; van der Meij et al., 2010). We hypoth-
esized that the use of fish oil containing our identified fatty acids
may have an adverse effect on the antitumor effects of chemo-
therapy. To test this, we fed tumor-bearing mice either purified
PIFAs or commercially available fish oil products and treated
them with cisplatin. We found that orally administered, pure
PIFAs induced resistance to cisplatin in our tumor models
(Figure 7A). Furthermore, a single oral dose of 100 ml of either
two different commercially available fish oil products or algae
extracts resulted in a neutralization of the antitumor effects of
cisplatin in both C26 and LLC tumors (Figure 7B; Figure S6A).
Administration of only fish oils or algae did not alter tumor growth
(Figure S6B). Orally administered EPA, the main component
of most fish oil products, that served as a control in both tumor
models had no effect. Importantly, both fish oil products
and the algae extract induced a complete resistance to chemo-
therapy at doses similar to the advised daily dose in humans.
These results provide additional support for the clinical rele-
vance of these fatty acids in the development of resistance to
chemotherapy.380 Cancer Cell 20, 370–383, September 13, 2011 ª2011 Elsevier InDISCUSSION
Our study reveals an important mechanism of resistance to
chemotherapy mediated by MSCs. We show that MSCs, acti-
vated by platinum-based chemotherapy, secrete unique fatty
acids that, in minute quantities, confer resistance to multiple
types of chemotherapy. We identified two distinct PIFAs, namely
KHT and 16:4(n-3), responsible for the induction of resistance by
the MSCs. We tested the purified PIFAs in our mouse models
and confirmed that they are extremely potent in inducing resis-
tance to chemotherapy. In contrast to other related polyunsatu-
rated fatty acids had no effect.
We provide several lines of evidence that point to the clinical
importance of platinum-based activation of MSCs in relation to
therapy response. First, MSCs are recruited to the circulation
of cancer patients with a tumor in situ. Second, in different
tumor-bearing mouse models, circulating MSCs were activated
by platinum-based chemotherapy in vivo and, subsequently,
induced resistance to chemotherapy. These findings indicate
that circulating MSCs will be exposed to chemotherapy at thec.
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Figure 7. Algae Extracts and Commercially Available Fish Oil Products Induce Resistance to Chemotherapy
(A) Tumor volume of C26 cells 4 days after treatment with either vehicle control, cisplatin (6 mg/kg) or cisplatin plus oral coadministration of HHT and 16:4(n-3),
respectively.
(B) Tumor growth of C26 cells either untreated or treated with cisplatin alone or with cisplatin plus orally administered fish oil products, algae extracts, or EPA, the
main component of most fish oil products.
Data are expressed as mean ± SEM (n = 6 mice per group). The graphs depict representative results from two individual experiments. Student’s t test, all
compared to chemotherapy alone: *p < 0.05, **p < 0.01.
See also Figure S7.
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Fatty Acids Induce Chemotherapy Resistancestart of treatment and that the number of circulating MSCs in
cancer patients is comparable to the number of MSCs sufficient
to confer chemoresistance in mouse models. Third, human and
murine MSCs secrete the specific PIFAs KHT and 16:4(n-3)
upon stimulation with platinum drugs, and these PIFAs can
indeed induce resistance in a human xenograft model. Fourth,
we found a significant increase in 16:4(n-3) hours after cisplatin-
based chemotherapy in patients compared to patients treated
with nonplatinum-based chemotherapy. Finally, it is commonly
observed that resistance to chemotherapy in patients develops
at all sites simultaneously, which, albeit speculative, could
support the presence of systemic factors such as the PIFAs
described here being responsible for the induction of resistance.
Platinum-based chemotherapy is the mainstay of care for
multiple types of cancer, including colorectal, ovarian, esopha-
geal, testicular, lung, and head and neck cancer (Kelland,
2007). Therefore, preventing the development of resistance in
these patients will be beneficial for a large group of patients.
Interventions directed against either MSCs or the identified
PIFAs may provide opportunities to enhance the efficacy of
chemotherapy and prevent the development of resistance.
Very little is known about the identified PIFAs belonging to the
omega-3 and oxo class of fatty acids, respectively. In general,
omega-3 and oxo fatty acids, are biologically active lipids with
specific receptors in both the cell membrane and nucleus.
(Wang and Dubois, 2010; Okuno et al., 2008). For KHT and
16:4(n-3) no receptors or downstream signaling pathways have
been described. We show that the PIFAs do not induce resis-
tance directly but induce the release of an intermediate factor(s)
by the host tissue in the plasma, which then directly prevents the
induction of apoptosis of tumor cells by chemotherapy.
By considering the mechanism of normal production of eicos-
anoids, we have been able to identify strategies to interfere withCanthe production of the identified PIFAs, and our results indicate
that this is a highly effective method to prevent resistance to
chemotherapy. We show that inhibition of intracellular calcium,
PLA2, TXAS, and COX-1, but not COX-2 inhibition, prevents
the release of PIFAs by MSCs. We show that the use of a
COX-1 inhibitor or a TXAS inhibitor in combination with plat-
inum-based chemotherapy significantly enhances the chemo-
therapy efficacy. In line with the somewhat disappointing
outcome of multiple clinical trials that have been performed
using COX-2 inhibitors in combination with chemotherapy
(Ko¨hne et al., 2008; Pierga et al., 2010), our findings suggest
that inhibition of COX-1, TXAS, or other enzymes leading to the
production of these resistance-inducing PIFAs may be more
effective.
Finally, our findings may also have important implications for
the current use of MSCs to promote tissue repair in clinical trials
for cancer-unrelated diseases such as immune disorders and
cardiovascular diseases (Psaltis et al., 2008; Djouad et al.,
2009). Our study demonstrates that MSCs can be specifically
activated to secrete cytoprotective factors. This finding may be
utilized in the design of clinical trials in which MSCs are used in
various nononcological diseases. Additionally, our findings may
have implications for the use of commercially available fish oil
products and algae by cancer patients during therapy. We
show that orally administered fish oil products in doses similar
to the converted advised daily dose in humans already induce
resistance to chemotherapy in mice. Therefore, the use of these
products during chemotherapy treatment should be avoided.
In summary our study identifies a systemic mechanism of
resistance via activation of MSCs by platinum-based chemo-
therapy with the subsequent release of two specific resis-
tance-inducing PIFAs. Our findings introduce important players
to the field of chemotherapy resistance and indicate that thecer Cell 20, 370–383, September 13, 2011 ª2011 Elsevier Inc. 381
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Fatty Acids Induce Chemotherapy ResistanceTXAS andCOX-1 pathwaymay be drugable pathways to prevent
PIFA-induced chemoresistance.
EXPERIMENTAL PROCEDURES
MSC Isolation and Culture
Murine MSCs were isolated from the BM or blood from syngenic mice using
immunomagnetic selection and primary cell culture. Human MSCs were iso-
lated from BM aspirates from healthy donors and cultured as previously
described (Prins et al., 2009). This was approved by the Institutional Ethical
Review Board of the University Medical Center (UMC) Utrecht, and written
informed consent was obtained from all donors. For identification, BM from
GFP+ mice (C57BL/6-Tg(UBC-GFP)30Scha/J mice; The Jackson Laboratory)
was used. MSC phenotype of the cultured MSCs was confirmed by FACS
analysis and multilineage differentiation.
Mouse Experiments
All animal procedures were approved by the UMC Utrecht Animal Care Ethics
Committee and are in agreement with current Dutch Law on Animal Experi-
ments. C26 colon carcinoma cells (1 3 106 cells), LLC cells (0.5 3 106 cells),
and MDA-MB-231 cells (3 3 106 cells) were s.c. implanted into BALB/c,
C57Bl/6, or athymic nudemice. Tumor size was assessed by caliper measure-
ments; volume was calculated ((L 3W2) 3 0.5). Chemotherapy was adminis-
tered intraperitoneally (i.p.), weekly at MTD level (cisplatin 6 mg/kg, oxaliplatin
10 mg/kg, carboplatin, 5-FU, and irinotecan at 100 mg/kg). Control mice
received appropriate vehicles. MSCs (both cultured or freshly isolated from
the BM) were administered either i.v. or s.c. at the start of chemotherapy
treatment. CM was harvested from the different cell types after 1–24 hr,
from both untreated cells (CM) and cells pretreated with different types of
chemotherapy for 30 min to 4 hr (CM+) a 100 ml of CM, or fractions was admin-
istered s.c. KHT precursor 12-HHT (Agins et al., 1987), 16:4(n-3) (Ishihara et al.,
2000), and control fatty acids were tested as described in Table S3. Further-
more, two commercially available fish oil products and homogenized extracts
from Ulva Pertussa algae were tested. The inhibitors MAFP (100 mM), DEDA
(100 mM), pyrrophenone (1 mM), U73122 (5 mM), D609 (100 mM), BAPTA AM
(1 mM), verapamil (10 mM), nicardipine (10 mM), indomethacin (10 and
100 mM), celecoxib (10 and 100 mM), SC560 (1 mM), ozagrel (1 mM), and fur-
egrelate (1 mM) were tested in vitro; indomethacin (2 mg/kg, s.c.) and ozagrel
(20 mg/kg, s.c.) were also tested in vivo for their ability to interfere with the
induction of resistance by MSCs.
Fractionation and MS Analysis
CMwas systematically fractionated as depicted in Figure 4A; each fractionwas
assessed for the ability to induce resistance in vivo. Fractions from CM+ were
compared to CM by ultra-high pressure liquid chromatography coupled
to Orbitrap mass spectrometer; differentially secreted substances were
analyzed with 5 ppm mass tolerance and subjected to database searches
usingNature LipidomicsGateway (www.lipidmaps.org) and tested individually.
In Vitro Experiments
C26 cells were treated in vitro with cisplatin (3 mM) or irinotecan (150 mM) alone
or combinedwith eitherCM+/CMorwith SFMsupplementedwith 4%plasma
harvested from nontumor-bearing mice 1 hr after treatment with either CM+ or
CM. Cell survival for all experiments was determined by counting the number
of viable cells, using trypan blue exclusion, 24 and 48 hr after start therapy.
Patient Samples
Blood samples were collected from 43 cancer patients before receiving
chemotherapy at the UMCUtrecht, The Netherlands. The study was approved
by the Institutional Ethical Review Board of the UMC Utrecht, and written
informed consent was obtained from all patients. Blood was collected in
a Cell Preparation Tube. Peripheral blood mononuclear cells (PBMCs) and
plasma were isolated. Plasma was stored immediately at 80C. The PBMCs
were washed once in RPMI and stored in 10% DMSO at 80C until analysis.
The number of MSCs in the PBMC fraction was quantified by flow cytometry.
MSCs were defined as CD45, CD90+, CD73+, and CD105+, and calculated
to the number of cells per milliliter of blood using the mononuclear cell count.382 Cancer Cell 20, 370–383, September 13, 2011 ª2011 Elsevier InThe levels of 16:4(n-3) were determined in the citrate plasma samples of ten
esophageal cancer patients and ten breast cancer patients.
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